Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality7/10

Kestra Medical Advances Q1 Results, Raises FY27 Revenue Guidance

Sep 14, 2026, 4:06 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong top-line growth, expanding margins, and higher FY27 guidance can re-rate multiple on improved growth visibility; however, continued GAAP losses keep downside risk if profitability stalls.

AI summary

What happened, with direct paths to the underlying reporting

Kestra reported F1Q27 revenue of $31.0M, up 60% year over year, with a gross margin of 56.5%. Management raised FY27 revenue guidance to $141M, signaling durable demand from the WCD market and in-network patients. Net liquidity remains robust (~$320M including committed loan availability), though GAAP net loss persisted, highlighting ongoing investment in commercialization and R&D.

Q1 FY2027 revenue $31.0M, up 60% YoY.
Gross margin 56.5% vs 45.7%.
FY27 revenue guidance raised to $141M, +48%.
Cash and investments $244.7M; total liquidity ~ $320M.
GAAP net loss $44.1M; Adj EBITDA loss $24.0M.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.